NCT06635889View on ClinicalTrials.gov

Intravesical Bupivacaine on Post-Operative Ureteroscopy Pain

PHASE2RecruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

December 13, 2024

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2029

Conditions
Nephrolithiasis
Interventions
DRUG

Bupivacaine

The dose plan is to use 50 ml of 0.25% bupivacaine which corresponds with a total dose of 125mg.

OTHER

Normal saline

Placebo of 50 ml of Normal Saline

Trial Locations (1)

60637

RECRUITING

The University of Chicago Medical Center, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER